258 related articles for article (PubMed ID: 18449940)
41. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
42. Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviors.
Miller SM; Roussi P; Daly MB; Buzaglo JS; Sherman K; Godwin AK; Balshem A; Atchison ME
Health Educ Behav; 2005 Oct; 32(5):654-67. PubMed ID: 16148211
[TBL] [Abstract][Full Text] [Related]
43. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
[TBL] [Abstract][Full Text] [Related]
44. The phases of disclosing BRCA1/2 genetic information to offspring.
Clarke S; Butler K; Esplen MJ
Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
[TBL] [Abstract][Full Text] [Related]
45. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
46. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.
Vos J; Otten W; van Asperen C; Jansen A; Menko F; Tibben A
Psychooncology; 2008 Aug; 17(8):822-30. PubMed ID: 18157792
[TBL] [Abstract][Full Text] [Related]
47. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
48. Exercise and healty weight in youth delay onset of breast cancer in women at highest risk.
Rollins G
Rep Med Guidel Outcomes Res; 2003 Nov; 14(23):7-8. PubMed ID: 14661631
[No Abstract] [Full Text] [Related]
49. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
50. High-risk women should have BRCA testing.
Cancer Discov; 2014 Feb; 4(2):139. PubMed ID: 24501290
[TBL] [Abstract][Full Text] [Related]
51. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
52. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.
Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C
Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048
[TBL] [Abstract][Full Text] [Related]
53. Hereditary breast and ovarian cancer syndrome.
ACOG Committee on Practice Bulletins
Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
[No Abstract] [Full Text] [Related]
54. Clinical implications of genetic testing for inherited breast and ovarian cancer risk.
Calzone KA
Nurs Spectr (Wash D C); 1998 Nov; 8(23):12-4. PubMed ID: 10542772
[No Abstract] [Full Text] [Related]
55. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
56. Optimal selection of individuals for BRCA mutation testing.
Evans DG; Lalloo F; Eccles D
J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
[No Abstract] [Full Text] [Related]
57. Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.
Fries MH; Holt C; Carpenter I; Carter CL; Daniels J; Flanagan J; Murphy K; Hailey BJ; Martin L; Hume R; Hudson G; Cadman M; Weatherly R; Nunes ME
Mil Med; 2002 Feb; 167(2):99-103. PubMed ID: 11873550
[TBL] [Abstract][Full Text] [Related]
58. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
[TBL] [Abstract][Full Text] [Related]
59. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
[TBL] [Abstract][Full Text] [Related]
60. Relevant risk for women with BRCA1 and BRCA2 mutations.
Furnival C
ANZ J Surg; 2007 May; 77(5):309. PubMed ID: 17497962
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
